Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Ramesh Bathina

Interventional Pain Medicine Aurora, IL Medical Doctor

NPI 1417060146 CMS profile 291126

1315 N Highland Ave # 105, Aurora, IL 60506

Open in the dashboard

General payments

$1,589

21 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Ramesh Bathina of Aurora, IL is reported in the CMS Open Payments database as having received $1,589 across 21 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 31st percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $150 3
2023 General $23 1
2022 General $165 2
2021 General $61 2
2020 General $1,112 12
2019 General $79 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ramesh Bathina
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Ramesh Bathina were reported at $0. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Ramesh Bathina Interventional Pain Medicine median Middle half National median
2019 $79 $684 $216–$2,079 $163
2020 $1,112 $382 $122–$1,109 $114
2021 $61 $552 $167–$1,554 $132
2022 $165 $605 $187–$1,924 $149
2023 $23 $671 $195–$1,915 $160
2024 $150 $684 $206–$1,837 $164
2025 $0 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Boston Scientific Corporation $1,406 18 payments
  2. SPR Therapeutics, Inc $105 2 payments
  3. Avanos Medical $79 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $797 17 payments
  2. Travel and Lodging $792 4 payments
Products named General payments · program years 2019–2024
  1. SUPERION Pain Management $1,068 7 payments
  2. General - Pain Management General - Pain Management_NMD $107 1 payment
  3. SPRINT PNS System $105 2 payments
  4. COOLIEF* COOLED RADIOFREQUENCY $79 1 payment
  5. GENERAL - PAIN MANAGEMENT Pain Management $44 5 payments
  6. Superion Pain Management $15 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

714

Median for Interventional Pain Management: 1,220

Drug cost

$9,680

Median for Interventional Pain Management: $39,344

Branded share of claims

60.4%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 414 $7,322
Oxycodone Hcl Generic 42 $663
Gabapentin Generic 55 $538
Acetaminophen-Codeine Acetaminophen With Codeine Brand 17 $277
Tramadol Hcl Generic 43 $239
Tizanidine Hcl Generic 61 $215
Celecoxib Generic 12 $174
Cyclobenzaprine Hcl Generic 32 $168
Amitriptyline Hcl Generic 12 $51
Alprazolam Generic 26 $32

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$37,538

Of which drugs: $741

Medicare patients

59

Average age 71

Services billed

1,402

40 women, 19 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 49%
Ischemic heart disease 32%
Chronic kidney disease 32%
COPD 31%
Depression 25%
Heart failure 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 33 912 $80
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 28 174 $17

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

21 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record